H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. - Florida Company Profile

DVHKP4N619V9

1X4B9

2025-12-05

2024-12-06

2002-04-18

1X4B9

Active

Non-Manufacturer

2024-12-06

2029-12-06

2025-12-05

REBECCA NICKLESON

1073339412

2024-12-02

View on NPI website

JOANNA C WEISS

EVP, CHIEF FINANCIAL OFFICER

8137451188

332B00000X - Durable Medical Equipment & Medical Supplies

Yes

+1 813-745-4673

36C24823N0028

View Award on USAspending website

AWARD

DELIVERY ORDER

48000.00

48000.00

48000.00

Department of Veterans Affairs

2022-10-01

PATHOLOGY CONSULTATIONS

621111: OFFICES OF PHYSICIANS (EXCEPT MENTAL HEALTH SPECIALISTS)

Q515: MEDICAL- PATHOLOGY

75N92019F00074

View Award on USAspending website

AWARD

DELIVERY ORDER

-82308.77

-82308.77

-82308.77

Department of Health and Human Services

2019-06-03

PRODUCTION ASSISTANCE FOR CELLULAR THERAPIES (PACT)- CELL PROCESSING FACILITIES CELL MANUFACTURING AND PROCESS DEVELOPMENT SERVICES FOR PCT0025-01: FVIII TCR-ENGINEERED TREG CELL PRODUCT

541712: RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT BIOTECHNOLOGY)

AN12: HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH

75N92019F00036

View Award on USAspending website

AWARD

DELIVERY ORDER

-30868.55

-30868.55

-30868.55

Department of Health and Human Services

2018-12-03

PRODUCTION ASSISTANCE FOR CELLULAR THERAPIES (PACT)- CELL PROCESSING FACILITIES CELL MANUFACTURING AND PROCESS DEVELOPMENT SERVICES FOR PCT0005-02: CRYOPRESERVATION TECHNICAL STUDY

541712: RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT BIOTECHNOLOGY)

AN12: HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH

2025-04-17

View on USAspending

Department of Defense

QUANTIFYING SPATIAL PROPERTIES OF IMMUNOSUPPRESSIVE MACROPHAGES IN PAPILLARY RENAL CELL CARCINOMA

328574.00

0.00

0.00

2025-03-20

View on USAspending

Department of Defense

DYNAMIC: DEVELOPMENT OF A BEHAVIORAL INTERVENTION FOR YOUNG ADULTS WITH ADVANCED CANCER

1619065.00

0.00

0.00

2025-04-01

View on USAspending

Department of Health and Human Services

LIBRE DEL CIGARRILLO: DEVELOPMENT OF AN MHEALTH SMOKING CESSATION APP TO EXTEND REACH OF A VALIDATED SMOKING CESSATION INTERVENTION FOR SPANISH-SPEAKING SMOKERS - PROJECT SUMMARY RACIAL/ETHNIC MINORITIES SUFFER DISPROPORTIONATELY FROM SMOKING RELATED MORBIDITY AND MORTALITY. FOUR OF THE FIVE LEADING CAUSES OF DEATH AMONG HISPANIC/LATINX (HEREAFTER REFERRED TO AS HISPANIC) INDIVIDUALS ARE SMOKING-RELATED; THUS, THERE IS A SIGNIFICANT PUBLIC HEALTH NEED TO REDUCE SMOKING IN THIS POPULATION. DESPITE THE HISPANIC POPULATION BEING THE LARGEST AND ONE OF THE FASTEST GROWING MINORITY POPULATIONS, THERE IS A DEARTH OF CULTURALLY APPROPRIATE SPANISH-LANGUAGE SMOKING CESSATION INTERVENTIONS. PREVIOUS WORK FROM OUR RESEARCH GROUP AND OTHERS HAS DEMONSTRATED UNIQUE BARRIERS FACED BY HISPANIC SMOKERS, SUCH AS LESS ACCESS TO CESSATION TREATMENTS AND OVERALL LESS UTILIZATION OF EVIDENCE-BASED CESSATION TREATMENTS. TO ADDRESS THE GAP IN AVAILABILITY OF SPANISH-LANGUAGE INTERVENTIONS, OUR TEAM USED A MULTI-STEP PROCESS TO DEVELOP A PRINTED SELF- HELP SMOKING CESSATION INTERVENTION FOR HISPANIC SMOKERS, “LIBRE DEL CIGARRILLO, POR MI FAMILIA Y POR MÍ: GUÍA PARA DEJAR DE FUMAR” (LDC; “FREE FROM CIGARETTES, FOR MY FAMILY AND FOR ME: GUIDE TO QUITTING SMOKING”). FINDINGS FROM OUR RANDOMIZED CONTROLLED TRIAL (RCT) WITH A NATIONWIDE SAMPLE (N=1,417), REVEALED HIGH EFFICACY OF OUR INTERVENTION THROUGH 24 MONTHS COMPARED TO USUAL CARE (AN NCI-PRODUCED SPANISH-LANGUAGE SELF-HELP BOOKLET). THERE ARE, HOWEVER, KEY LIMITATIONS WITH THE PRINT MODALITY, INCLUDING THE INABILITY TO ACCESS INTERVENTION CONTENT IN REAL TIME AND LIMITED ABILITY TO ENHANCE ENGAGEMENT WITH THE INTERVENTION CONTENT. GIVEN THE INCREASING POPULARITY OF DIGITAL INTERVENTIONS AND HIGH OWNERSHIP OF SMARTPHONES AMONG HISPANICS (91%) A SMARTPHONE APP DELIVERING EVIDENCE-BASED SMOKING CESSATION CONTENT CAN OVERCOME THESE BARRIERS AND HAS ADDITIONAL STRENGTHS. THE GOALS OF THIS STUDY ARE TO ADAPT OUR VALIDATED PRINTED SMOKING CESSATION INTERVENTION FOR SPANISH-SPEAKING SMOKERS INTO A SMARTPHONE APP (AIM 1) AND TO CONDUCT A THREE-ARM PILOT RCT TO EXAMINE FEASIBILITY AND ACCEPTABILITY OF THE SMARTPHONE APP INTERVENTION AND FEASIBILITY OF THE FUTURE CLINICAL TRIAL (AIM 2). THE SMARTPHONE APP VERSION WILL BE BASED ON OUR RECENT FORMATIVE RESEARCH, BIDIRECTIONAL STAKEHOLDER ENGAGEMENT, AND VALIDATED CONTENT THAT WE HAVE ALREADY TRANSCREATED AND WILL BE ENHANCED VIA FUNCTIONALITY OF THE APP (AIM 1). AFTER THE LIBRE DEL CIGARRILLO SMARTPHONE APP IS DEVELOPED (AIM 1), PARTICIPANTS (N=120) WILL BE RANDOMLY ASSIGNED TO EITHER THE: (1) NEWLY DEVELOPED LIBRE DEL CIGARRILLO SMARTPHONE APP; (2) EXISTING LIBRE DEL CIGARRILLO BOOKLETS; OR (3) NCI SMOKEFREE TXT (TEXT) PROGRAM IN SPANISH (STANDARD-OF-CARE-COMPARATOR) (AIM 2). WE WILL EVALUATE FEASIBILITY AND ACCEPTABILITY OF THE SMARTPHONE APP AND FUTURE CLINICAL TRIAL FEASIBILITY USING A PRIORI BENCHMARKS. WE WILL ALSO MEASURE CHANGES IN INTERMEDIARY SMOKING-RELATED VARIABLES (E.G., MOTIVATION, SELF-EFFICACY) AND SMOKING BEHAVIOR. THIS R34 REPRESENTS THE NEXT LOGICAL STEP IN A SYSTEMATIC APPROACH TO DEVELOP SCALABLE, COST-EFFECTIVE, AND ACCESSIBLE SMOKING CESSATION INTERVENTIONS FOR SPANISH- SPEAKING INDIVIDUALS WHO SMOKE. THIS WORK HAS POTENTIAL TO EXPAND DISSEMINATION OF SMOKING CESSATION INTERVENTIONS TO AN UNDERSERVED POPULATION, AND ULTIMATELY REDUCE TOBACCO-RELATED HEALTH DISPARITIES.

316873.00

0.00

0.00

2025-03-24

View on USAspending

Department of Health and Human Services

STRUCTURE-FUNCTION STUDIES OF LAG3 INTERACTIONS WITH ANTIBODIES AND CELLULAR LIGANDS - PROJECT ABSTRACT IN THIS PROPOSAL, WE WILL DETERMINE HOW ANTIBODIES AND CELLULAR LIGANDS REGULATE THE IMMUNOSUPPRESSIVE FUNCTION OF LYMPHOCYTE-ACTIVATION GENE 3 (LAG3). LAG3 IS AN IMMUNE CHECKPOINT PROTEIN THAT SUPPRESSES T CELL ACTIVATION UPON ENGAGEMENT OF THE LIGANDS MAJOR HISTOCOMPATIBILITY COMPLEX TYPE II (MHCII) OR FIBRINOGEN-LIKE 1 (FGL1). INHIBITORS OF LAG3 HAVE BEEN WIDELY INVESTIGATED AS POTENTIAL IMMUNOTHERAPIES GIVEN THEIR ABILITY TO REVERSE LAG3-MEDIATED IMMUNOSUPPRESSION IN THE TUMOR MICROENVIRONMENT. THESE STUDIES EVENTUALLY LED TO FDA APPROVAL OF AN ANTIBODY TARGETING LAG3, IN COMBINATION WITH A PD1 INHIBITOR, FOR THE TREATMENT OF METASTATIC MELANOMA. THIS BREAKTHROUGH MARKED LAG3 AS THE “THIRD CHECKPOINT” TO BE SUCCESSFULLY TARGETED IN THE CLINIC FOLLOWING PD1 AND CTLA4, AND A MYRIAD OF OTHER LAG3-BASED THERAPIES ARE NOW ACTIVELY UNDER CLINICAL EVALUATION AS CANCER IMMUNOTHERAPIES. THE RATIONAL DESIGN OF LAG3-TARGETING THERAPEUTICS HAS BEEN CHALLENGING DUE TO OUR INCOMPLETE UNDERSTANDING OF LAG3 MOLECULAR BIOLOGY. RECENT, UNEXPECTED FINDINGS HAVE SHOWN THAT ANTIBODIES TARGETING ALL FOUR DOMAINS OF THE LAG3 PROTEIN CAN FUNCTION AS EFFECTIVE IN VITRO INHIBITORS, AND THAT A SUBSET OF THESE ANTIBODIES DO NOT BLOCK LAG3-LIGAND INTERACTIONS. THUS, IT IS UNCLEAR IN WHICH CONTEXTS LIGAND BLOCKADE IS REQUIRED FOR OPTIMAL LAG3 IMMUNOTHERAPY RESPONSES. ANOTHER MAJOR GAP IN OUR KNOWLEDGE IS THAT WE HAVE NOT BEEN ABLE TO VISUALIZE HOW LAG3 ENGAGES MHCII AND FGL1. THIS LACK OF STRUCTURAL INFORMATION HAS PREVENTED US FROM DETERMINING THE MOLECULAR MECHANISMS USED BY LIGANDS TO CONTROL LAG3 FUNCTION. LASTLY, WE DO NOT KNOW WHETHER MECHANISMS OF LAG3 INHIBITION, SUCH AS BLOCKADE OF LAG3 DIMERIZATION OR DISRUPTION OF LAG3-LIGAND INTERACTIONS, ARE ASSOCIATED WITH DIFFERENT IMMUNOTHERAPY RESPONSES IN VIVO. TO ADDRESS THE ISSUES ABOVE, WE ARE TAKING A MULTIDISCIPLINARY APPROACH THAT LEVERAGES OUR EXPERTISE IN STRUCTURAL IMMUNOLOGY, BIOLOGICS DEVELOPMENT, AND MELANOMA IMMUNOTHERAPY. IN AIM 1, WE WILL ANSWER THE QUESTION, “HOW DO DIFFERENT LIGANDS INFLUENCE LAG3?” THROUGH A SERIES OF RIGOROUS STRUCTURE-FUNCTION STUDIES. IN AIM 2, WE WILL DETERMINE HOW THE UNIQUE BINDING MODES OF LAG3 AGONIST AND ANTAGONIST ANTIBODIES DICTATE THEIR FUNCTION. IN AIM 3, WE WILL USE MELANOMA MOUSE MODELS TO ASSESS THE THERAPEUTIC POTENTIAL OF DIFFERENT CLASSES OF ANTI- LAG3 ANTIBODIES. COLLECTIVELY, THIS RESEARCH WILL PROVIDE FUNDAMENTAL INSIGHT INTO LAG3 IMMUNOBIOLOGY AND WILL OPEN NEW AVENUES FOR THE DEVELOPMENT OF OPTIMAL LAG3 IMMUNOTHERAPIES FOR MELANOMA.

549962.00

0.00

0.00

2025-04-10

View on USAspending

Department of Health and Human Services

DEFINING IMPACT OF IN SITU ACTIVATION OF CD40 AND TYPE 1 INTERFERON SIGNALING ON THETME AND SYSTEMIC T CELL IMMUNITY IN MURINE MODELS AND CANCER PATIENTS - PROJECT SUMMARY RECENT ADVANCES IN CANCER IMMUNOTHERAPIES HAVE REVOLUTIONIZED LUNG CANCER TREATMENT PARADIGMS. HOWEVER, MANY PATIENTS DERIVE LITTLE OR NO BENEFIT FROM FDA APPROVED IMMUNE CHECKPOINT INHIBITORS (ICI). A HOST OF CLINICAL STUDIES HAVE SHOWN THAT PRE-EXISTING TUMOR-REACTIVE T CELLS ARE CRITICALLY IMPORTANT TO ACHIEVE BENEFIT FROM ICI. THEREFORE, AUGMENTING THE NUMBER AND FUNCTIONALITY OF TUMOR-REACTIVE T CELLS COULD PAVE THE WAY FOR MORE EFFECTIVE CANCER TREATMENTS. ONCOLYTIC VIRUSES (OVS) HAVE BEEN DEVELOPED FOR THEIR ABILITY TO SPECIFICALLY REPLICATE IN CANCER CELLS LEADING TO CANCER CELL LYSIS BUT NOT CYTOTOXICITY TOWARDS NORMAL CELLS. RECENT STUDIES INDICATE THAT STIMULATION OF HOST ANTI-TUMOR IMMUNITY IS ALSO A KEY MECHANISM OF ACTION OF OVS. USING A NOVEL CONDITIONALLY REPLICATIVE ADENOVIRUS TYPE 5 THAT EXPRESSES TWO POWERFUL INNATE IMMUNITY STIMULATORS, THE STUDIES PROPOSED HERE CAN LEAD TO THE DEVELOPMENT OF HIGHLY EFFECTIVE OV-BASED THERAPEUTIC STRATEGIES TO KILL TUMOR CELLS AND SIMULTANEOUSLY ENHANCE AN ANTI-TUMOR T CELL RESPONSE. ENGAGEMENT OF CD40 EXPRESSED ON DENDRITIC CELLS (DCS) BY CD40 LIGAND (CD40L) LEADS TO ACQUISITION OF CRUCIAL CROSS-PRIMING FUNCTION TO ACTIVATE CD8 T CELLS. MEM40 IS A CHIMERIC CD40L ENGINEERED FOR STABLE CELL SURFACE EXPRESSION. IN ADDITION TO PRO-INFLAMMATORY AND ANTI-VIRAL FUNCTIONS, TYPE 1 IFNS ALSO FUNCTION AS CRUCIAL ACTIVATORS OF DCS. OUR PRECLINICAL STUDIES IN MOUSE MELANOMA AND LUNG TUMOR MODELS INDICATE THAT INTRALESIONAL ADMINISTRATION OF MEM40 + IFNΒ EXPRESSING ONCOLYTIC ADENOVIRUS (MEM-288) WE DEVELOPED INDUCES A ROBUST SYSTEMIC T CELL RESPONSE THAT IN SYNERGY WITH ICI IS CAPABLE OF SIGNIFICANTLY CURTAILING ABSCOPAL TUMOR GROWTH. A KEY EFFECT OF CD40L AND IFNΒ EXPRESSION IN THE TUMOR MICROENVIRONMENT (TME) WAS THE ENHANCEMENT OF DC ACTIVATION AND MIGRATION TO DRAINING LYMPH NODES TO INDUCE T CELL PRIMING. THESE FINDINGS PROMPTED US TO DEVELOP A NOVEL CONDITIONALLY REPLICATIVE ONCOLYTIC ADENOVIRUS (MEM-288) THAT EXPRESSES A MEMBRANE-STABLE CD40L (MEM40) AND IFNΒ. A PHASE 1 FIRST-IN-HUMAN DOSE ESCALATION CLINICAL TRIAL OF SINGLE AGENT MEM-288 IS NEARING COMPLETION WHILE A COMBINATION TRIAL OF MEM-288 WITH ICI IN NSCLC PATIENTS IS EXPECTED TO BEGIN IN FALL 2023. A PRIMARY GOAL OF STUDIES PROPOSED HERE IS TO DEFINE MEM-288 CLINICAL ACTIVITY IN NSCLC PATIENTS FROM BOTH TRIALS AND ASSESS IMMUNE STIMULATORY EFFECTS OF MEM-288 IN THE TUMOR MICROENVIRONMENT (TME) AND ABILITY TO GENERATE A SYSTEMIC ANTI-TUMOR T CELL RESPONSE. TWO SPECIFIC AIMS ARE PROPOSED: AIM 1: DEFINING IMPACT OF IN SITU ACTIVATION OF CD40 AND TYPE 1 IFN SIGNALING ON DC AND T CELL RESPONSES IN TUMOR MODELS. AIM 2: IMPACT OF ONCOLYTIC VIRUS (MEM-288) INDUCED CD40 AND TYPE 1 IFN SIGNALING ON TME REMODELING AND SYSTEMIC T CELL RESPONSES IN NSCLC PATIENTS.

874388.00

0.00

0.00

2022-11-04

Complaint

12902 USF MAGNOLIA DRIVE, TAMPA, FL, 33612

Safety

Partial

59-3238634

% YVETTE M LYONS TREMONTI

Government Instrumentality, Title-Holding Corporation, Charitable Organization, Agricultural Organization, Board of Trade, Pleasure, Recreational, or Social Club, Fraternal Beneficiary Society, Order or Association, Voluntary Employees' Beneficiary Association (Non-Govt. Emps.), Domestic Fraternal Societies and Associations, Teachers Retirement Fund Assoc., Benevolent Life Insurance Assoc., Burial Association, Credit Union, Mutual Insurance Company or Assoc. Other Than Life or Marine, Corp. Financing Crop Operations, Supplemental Unemployment Compensation Trust or Plan, Employee Funded Pension Trust (Created Before 6/25/59), Post or Organization of War Veterans, Legal Service Organization, Black Lung Trust, Multiemployer Pension Plan, Veterans Assoc. Formed Prior to 1880, Trust Described in Sect. 4049 of ERISA, Title Holding Co. for Pensions, etc., State-Sponsored High Risk Health Insurance Organizations, State-Sponsored Workers' Compensation Reinsurance, ACA 1322 Qualified Nonprofit Health Insurance Issuers, Apostolic and Religious Org. (501(d)), Cooperative Hospital Service Organization (501(e)), Cooperative Service Organization of Operating Educational Organization (501(f)), Child Care Organization (501(k)), Charitable Risk Pool, Qualified State-Sponsored Tuition Program, 4947(a)(1) - Private Foundation (Form 990PF Filer)

1994-07

Type of organization and use of contribution: A public charity. Deductibility Limitation: 50% (60% for cash contributions)